Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive October 1, 2011	30 Years of Pharma: Perspective in Numbers, Part 2 Top 10 pharmaceutical companies by market share.
Managed Care August 2004	MCOs, Drug Manufacturers Have Lots of PR Work to Do Managed care companies, and pharmaceuticals especially, receive disheartening numbers in a consumer satisfaction poll.
Managed Care April 2004	Headlines on Deadline The least insured of the major medical services is the pharmaceutical benefit, according to the Pharmaceutical Research and Manufacturers of America.
The Motley Fool January 25, 2007 Brian Lawler	Johnson & Johnson's Earnings Glee Johnson & Johnson keeps growing, even if the pharmaceutical segment is a bit sluggish. Investors, take note.
The Motley Fool July 25, 2011	West Pharmaceutical Services Earnings Preview West Pharmaceutical Services will unveil its latest earnings on Thursday, July 28.
The Motley Fool July 28, 2011	Medicis Pharmaceutical Earnings Preview Medicis Pharmaceutical will unveil its latest earnings on Tuesday, August 2.
The Motley Fool July 18, 2011 Travis Hoium	Pharmaceutical Product Development Shares Popped: What You Need to Know Shares of research group Pharmaceutical Product Development jumped as much as 18% this morning on potential merger talks.
CRM February 2, 2003 David Myron	Vertical Focus: Pharmaceuticals Pharmaceutical companies are prolonging the good health of their customers -- and the CRM industry. Largely influenced by retiring Baby Boomers, lack of FDA-approved drugs in the pipeline, and direct selling campaigns, the industry is becoming more customer-focused.
The Motley Fool January 27, 2011 Seth Jayson	Here's How Pharmaceutical Product Development May Be Failing You Here's the current margin snapshot for Pharmaceutical Product Development and some of its sector and industry peers and direct competitors.
InternetNews July 27, 2010	Oracle Debuts Drug-Tracking App for Big Pharma With its new Pedigree and Serialization Manager, Oracle is pitching an application to pharmaceutical companies that will enable them to track the movement of drugs across the supply chain.
The Motley Fool January 31, 2011 Brian Orelli	Pharma Goes Back to School But will it produce more drugs? The pharmaceutical industry is headed back to school, with a number of large drugmakers announcing partnerships with universities.
Information Today October 2000	Dialog One Releases New Pharmaceutical Module With Dialog One Pharmaceutical, users can discover what new drugs their competitors have in development, follow regulatory information for pharmaceuticals and medical devices, and uncover lucrative drug licensing opportunities worldwide...
The Motley Fool January 26, 2005 Stephen D. Simpson	Sanofi's Balancing Act A broad portfolio of drugs helps the French pharmaceutical stay ahead of its peers. It's a good option for investors who want a strong growth stock in the pharmaceutical space but don't want to take on the risks of turnarounds or litigation.
The Motley Fool February 12, 2007 Brian Lawler	I Love Drug Stocks This Valentine's Day, leave a special place in your heart for drug stocks.
The Motley Fool February 22, 2005 Rich Duprey	Merger Mania Besets Japanese Pharmaceuticals A new law spurs megamergers in Japan's pharmaceutical industry. Stocks of companies seen as particularly interesting, including Eisai, Mitsubishi Pharma, and Shionogi, all jumped more than 2%.
The Motley Fool October 27, 2005 Stephen D. Simpson	A Balanced Attack for Glaxo A broad suite of drugs, a huge sales force, and a solid pipeline make GlaxoSmithKline an appealing pharmaceutical company. The problem for investors is that it's all valued into the stock.
The Motley Fool November 29, 2010 Seth Jayson	Here's How Teva Pharmaceutical May Be Failing You Here's the margin picture for Teva Pharmaceutical over the past few years.
The Motley Fool September 25, 2008 Brian Lawler	Eli Lilly's Dose of Disclosure The pharmaceutical pledges public reports of its dealings with doctors.
The Motley Fool July 11, 2007 Brian Lawler	Not All Pharmaceutical Markets Are the Same The case of China's former FDA leader highlights the issues facing the country's pharmaceutical industry. Investors, take note.
Chemistry World June 24, 2011 Hepeng Jia	Pharma pollution is out of control in China Active pharmaceutical ingredients pollution problems seem to continue even after the Chinese government increased efforts to reduce environmental pollution from drug makers.
The Motley Fool June 11, 2007 Brian Lawler	Johnson & Johnson's Pretty Pipeline While there are concerns about other parts of Johnson & Johnson (for example, its medical device segment), its pharmaceutical division has a robust pipeline of compounds in development that should pay off in the long haul.
Pharmaceutical Executive November 1, 2011 Josef Bossart	Pharma Revolution Recalibrated Industry critics point to a lag in NME approvals as proof of innovation stagnation, but combination products and new delivery systems are quietly saving lives, and bringing in big dollars.
The Motley Fool February 4, 2008 Chuck Saletta	Best International Stock: Teva Pharmaceutical A quick summary of Israel's Teva Pharmaceutical, the world's largest generic drugmaker.
The Motley Fool October 26, 2005 Stephen D. Simpson	Cardinal's Tweet More Sweet Changes at the giant manufacturer, distributor, and service provider in the health-care industry are working out well, but the stock price already reflects it.
Pharmaceutical Executive October 1, 2005 Philip A. George	Backpage: Under Surveillance Doctors and consumers don't doubt that pharma benefits society. But in the eyes of the public, industry efforts to monitor postmarket safety come up short.
AskMen.com	Drug CEOs: Not That Rich? Billionaire Mayor Michael Bloomberg defended multibillion-dollar pharmaceutical companies and their chief executives on Friday, declaring that they "don't make a lot of money" and shouldn't be scapegoats in the health care debate.
InternetNews January 23, 2004 Michael Singer	Oracle Makes a Play for Life Sciences The business software giant acquires SiteWorks Solutions to capitalize on drug companies that need to run clinical trials.
Information Today	ebrary Announces New Ebook Program for Pharmaceutical Companies From research and development, to manufacturing and distribution, to marketing and sales, ebrary provides the ebooks and digital content services that can help pharmaceutical companies increase productivity, while extending their information budgets.
The Motley Fool August 5, 2005 Stephen D. Simpson	Can This Cardinal Sing? If Cardinal Health succeeds in its plans to return more capital to shareholders, this could become an interesting income play. This stock is worth keeping an eye on for the future.
Managed Care July 2007	The Formulary Files Chronic disease treatments contribute significantly to spending growth.
The Motley Fool June 2, 2009 Brian Orelli	ASCO's Big Winner Despite the massive changes in value that some small-cap biotech companies have seen before and during this year's American Society of Clinical Oncology annual meeting, the big winner from the confab is actually large pharmaceutical companies.
The Motley Fool January 24, 2006 Stephen D. Simpson	Reddy, Set, Go! After a tough stretch, leading Indian pharmaceutical company Dr. Reddy's may be ready to move again. This is still a turnaround story, though, so investors unable or unwilling to assume above-average risk should probably steer clear.
Chemistry World February 2008 Derek Lowe	Column: In the Pipeline Does it matter whether or not a pharmaceutical company is run by a chemist?
The Motley Fool August 26, 2010 Travers & Jayson	Will BioMarin Pharmaceutical Burn You? Is BioMarin Pharmaceutical on strong financial footing?
Chemistry World March 25, 2010 Rebecca Trager	Big pharma scores in US healthcare reform President Obama has signed the biggest US healthcare reform since the 1960s, and although it is largely seen as a victory for the pharmaceutical industry, some analysts are characterising it as a 'double-edged sword'.
The Motley Fool August 17, 2007 Brian Lawler	The Perfect Pharma Acquisition The pharmaceutical industry has been busy consolidating in the past year. With so much buying and selling going on, here is speculation on what would constitute the perfect pharma acquisition.
The Motley Fool November 12, 2009 Brian Orelli	How Do You Say 'Drug Development' in Mandarin? Drug giant Novartis announces that it's heading to China in a big way.
Chemistry World October 11, 2007 Hepeng Jia	China's Drug Industry Set to Take Off Producing cheap drugs for the developing world could allow Chinese pharmaceutical firms to capture a bigger share of the international market, industry experts suggest.
Pharmaceutical Executive February 1, 2011 Stan Bernard	Are You Trained to Compete and Win? With the impact of the sales rep in decline, it's time to beef up training for other pharma functions to fill the gap in a competitive marketplace
Pharmaceutical Executive March 1, 2012 B. Brett Heavner	Judging a Pill by its Cover Pharmaceutical trade dress is an effective marketing tool that helps boost product recognition for consumers. It's worth protecting.
Pharmaceutical Executive March 1, 2013	China and the Emerging Markets Challenge: Why Big Pharma Must Embrace a New Strategy With health reform already tagged as a key domestic priority, their policies will pose new opportunities and challenges for Big Pharma companies active in China.
The Motley Fool December 4, 2008 Brian Orelli	Drug Deals Require Cash Pharmaceutical companies have been hoarding cash -- patiently waiting for good prices. And it looks like that time has arrived. Take a look at some players in the pharmaceutical field.
Pharmaceutical Executive February 1, 2006 Peter Pitts	Opinion: The Media Attacks Ghostwritten Articles Is it right and appropriate for pharmaceutical companies to be involved in the drafting of medical journal articles that are based on their own studies of their own products.
The Motley Fool November 30, 2010 Brian Orelli	A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist.
Chemistry World March 2007 Derek Lowe	Opinion: In the Pipeline Do the benefits of pharmaceutical company mergers really outweigh the costs?
IndustryWeek December 1, 2008 Jill Jusko	Focus on the Process Industries: Pharmaceuticals: Reworking the Pharma Supply Chain As multiple forces challenge the pharmaceutical industry, supply chains get a new look.
The Motley Fool December 6, 2004 Brian Gorman	Pill-Popping Nation Americans are using more prescription drugs. Unfortunately for big pharma investors, pharmaceutical companies' benefits from these trends are tempered by other factors.
The Motley Fool December 13, 2004 Brian Gorman	Which Medications Are Your Best Bets? Consumer Reports' effort to rate drugs offers a marketing lesson to pharmaceutical companies.
The Motley Fool August 31, 2011 Brian Orelli	Antibodies: They're Not Just for Fighting Infection Anymore Therapeutic antibodies have continued to evolve since the first, OKT3, was approved back in 1986. Biotech investors had better pay attention, lest the technology passes them by.
Chemistry World February 7, 2013 Maria Burke	GSK commits to AllTrials data disclosure GlaxoSmithKline has become the first pharmaceutical company to sign up to a high-profile campaign to make detailed data on all clinical trials available to the public.